PIK3CA and cancer: Although there are no direct FOXC1 inhibitors described to date, previous reports have indicated that FOXC1 is regulated by the phosphatidylinositol 3-kinase (PI3K)-AKT signaling [53], a pathway that is being aggressively targeted with multiple therapeutics across cancer types.